SARS-CoV-2 and COVID-19 : What are our options? Where should we focus our attention on to find new drugs and strategies?
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Travel medicine and infectious disease - 37(2020) vom: 25. Sept., Seite 101685 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Magro, Giuseppe [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 30.10.2020 Date Revised 28.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.tmaid.2020.101685 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM30918228X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM30918228X | ||
| 003 | DE-627 | ||
| 005 | 20240328234528.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.tmaid.2020.101685 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1352.xml |
| 035 | |a (DE-627)NLM30918228X | ||
| 035 | |a (NLM)32334088 | ||
| 035 | |a (PII)S1477-8939(20)30153-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Magro, Giuseppe |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SARS-CoV-2 and COVID-19 |b What are our options? Where should we focus our attention on to find new drugs and strategies? |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.10.2020 | ||
| 500 | |a Date Revised 28.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Baricitinib | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Corona virus cycle | |
| 650 | 4 | |a Coronavirus | |
| 650 | 4 | |a Coronaviruses | |
| 650 | 4 | |a Drugs | |
| 650 | 4 | |a Hydroxychloroquine | |
| 650 | 4 | |a Remdesivir | |
| 650 | 4 | |a SARS-CoV | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Strategies | |
| 650 | 4 | |a Targets | |
| 650 | 4 | |a Therapies | |
| 650 | 4 | |a Tocilizumab | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Travel medicine and infectious disease |d 2003 |g 37(2020) vom: 25. Sept., Seite 101685 |w (DE-627)NLM16457655X |x 1873-0442 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2020 |g day:25 |g month:09 |g pages:101685 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.tmaid.2020.101685 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2020 |b 25 |c 09 |h 101685 | ||